Healthcare facilities across England are experiencing disruptions in the availability of frequently used medications, according to data gathered through freedom of information requests. The affected drugs include aspirin, co-codamol (a paracetamol and codeine combination), and ramipril, a medication for managing high blood pressure. Nine NHS trusts reported shortages of at least two of these three medications, while one trust encountered supply problems with all three.
Research by an expert in global health supply chains at University College London examined stock levels across the 184 NHS trusts in England. Among the 60 trusts that provided information, aspirin represented the most widespread shortage, with 26 of 42 responding trusts (62%) reporting supply disruptions between last December and March this year. For co-codamol, 13 of 42 trusts (31%) experienced shortages, with some facilities facing continuous disruption for extended periods. Ramipril shortages affected seven of 43 responding trusts (16%), though one trust chose to pay premium prices to maintain uninterrupted access to the medication.
The shortages reflect broader vulnerabilities in pharmaceutical supply chains that have developed in recent years, stemming from trade tensions, global conflicts, and manufacturing challenges. While drug scarcities have historically affected specialist medications, current problems increasingly involve generic drugs that are less expensive to produce. Pharmacists have characterized the situation as a national crisis, with some patients unable to access their regular medications for weeks.
Data indicates that emergency preparedness for supply disruptions remains limited within the NHS system. Nearly all trusts that responded reported having no contingency plans for managing shortages, and a substantial majority did not report their supply problems to national health authorities. A health department spokesperson indicated awareness of ramipril supply constraints and stated that serious shortage protocols have been implemented. The government emphasized ongoing efforts with manufacturers to resolve disruptions across all three affected medications.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI